Bladder clinic marketing: leak cure claims, laser and chair offers, mesh pages, supplies and urgent signs

A bladder clinic speaks to people who plan each outing around a restroom, who stopped running or lifting their grandchildren because of leaks, who wake several times a night, and to the adult children who notice that a parent has started to stay home. The clinic may sit inside a urology or OB-GYN group, a urogynecology practice, a primary care or geriatric practice, a pelvic floor physical therapy clinic or a med spa that has added a “bladder” service. This guide covers what the federal sources say about bladder control problems, how to write about treatment without promising to end leaks, how to describe laser, radiofrequency and chair offers in the terms of the FDA record, how to write about mesh and surgery, how free pads and supplies meet the federal rules on inducements, and where the urgent signs belong.

Nine related topics have their own guides and are not repeated here. Urology group marketing is covered in our guide to urology practice marketing, and therapy programs in our guide to pelvic floor therapy marketing. Women’s care is covered in our guides to OB-GYN practice marketing and menopause clinic marketing, and men’s clinics in our guide to men’s health clinic marketing. Device claims are covered in full in our guide to medical device marketing claims, aesthetic services in our guide to med spa marketing ideas, supply companies in our guide to DME supplier marketing, and nerve conditions in our guide to neurology practice marketing. For laser and radiofrequency vaginal treatments in more depth, see our guide to vaginal rejuvenation advertising rules.

What NIDDK and MedlinePlus say

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) leads federal research on bladder control, and MedlinePlus from the National Library of Medicine publishes the federal patient pages. The points that shape a bladder clinic’s marketing:

• The NIDDK page Bladder Control Problems (Urinary Incontinence) (last reviewed July 2021, about five years old) says a person has urinary incontinence when urine leaks accidentally, tells people to talk with a health care professional about bladder control problems right away, and says treatment depends on the type of urinary incontinence a person has. It says childbirth, menopause, aging and other health factors can cause or contribute to bladder control problems in women, and aging and prostate problems may cause urinary incontinence in men.
• The NIDDK page Symptoms and Causes of Bladder Control Problems (last reviewed July 2021) tells people to see a health care professional right away if they cannot pass urine or empty the bladder, urinate eight or more times a day, see blood in their urine, or have bladder infection symptoms such as painful urination, and says these symptoms can signal a serious health problem. It names nerve damage from diabetes, stroke, Parkinson’s disease, multiple sclerosis and spinal cord injury among the causes, and says incontinence after prostate cancer treatment can get better over time.
• The NIDDK page Treatments for Bladder Control Problems (last reviewed July 2021) starts with lifestyle changes, bladder training and pelvic floor muscle exercises, and says that if those do not improve symptoms, a health care professional may prescribe medicine, a medical device, a bulking agent or, as a last resort, surgery. It says a physical therapist trained in pelvic floor therapy can help with the exercises, that sling surgery with synthetic mesh can be successful and safe but complications can occur in some women, and that even after treatment a person may still leak urine from time to time.
• The MedlinePlus Urinary Incontinence page (last updated January 9, 2024, older than two years) says the condition can get better with proper treatment, that treatment depends on the type and cause, and that a person may need a combination of treatments.
• The MedlinePlus encyclopedia article Urinary incontinence (review date October 1, 2024) tells people to call 911 or go to an emergency room if they suddenly lose control over urine and have difficulty talking, walking or speaking, sudden weakness, numbness or tingling in an arm or leg, loss of vision, loss of consciousness or confusion, or loss of bowel control. It tells people to contact their provider for cloudy or bloody urine, dribbling, a frequent or urgent need to urinate, pain or burning when urinating, trouble starting the urine flow, or fever.

The NIDDK pages are about five years old, so before relaying them we checked for anything newer. A search of FDA drug label data through openFDA on October 30, 2026 returned labels updated as recently as September 2026 for overactive bladder and urge incontinence; the approved drug labels we found are indicated for the treatment of symptoms, and none describes a cure. A search of FDA device classification and 510(k) data on the same day showed clearances as recent as September 2026 for non-implantable electrical stimulators for incontinence, each tied to its own indications for use. The NIDDK description of treatment as a sequence of options, with leaks possible even after treatment, therefore still stands. Run the same check at each review.

Two points shape the marketing. First, the sources describe bladder control as something that improves with the right treatment for the type and cause, not as something one product ends, so a page that promises “no more leaks” says more than any source here. Second, leaks can be the first sign of a nerve problem, an infection or a blockage, so the urgent signs belong above any offer.

“Cure your leaks” and other claims that need rewriting

Google’s search suggestions, which we checked on October 30, 2026, offer “cure urinary incontinence naturally” and “cure stress incontinence” to a person who starts typing “cure urinary incontinence”, “laser for incontinence reviews” and “laser treatment for incontinence cost” after “laser for incontinence”, “kegel chair therapy” and “kegel chair price” after “kegel chair”, and “overactive bladder natural supplements” after “overactive bladder natural”. A clinic page can answer those questions honestly: say treatment depends on the type and cause, list the options NIDDK names in its order, and say a clinician explains the choices, risks and costs at the visit.

Phrases that need rewriting:

• “Cure bladder leaks for good.” NIDDK says a person may still leak from time to time after treatment, and our label search found no approved drug described as a cure. Remove it, and say treatment aims to reduce leaks and the plan depends on the type and cause.
• “Stop leaks in one session.” A result promise with no source. Remove it.
• “No surgery, no pills, no downtime.” An implied claim that the clinic’s option is free of risk and better than the others. Remove it, and state the risks a clinician lists for the procedure.
• “Better than Kegels.” A comparison claim that needs evidence for that device against that exercise program. Remove it unless a named, published source supports it.
• “9 out of 10 women are dry after treatment.” An outcome number with no source. Remove it unless it is quoted from a named, published source with its date and limits.
• “Leaks are a normal part of aging, but you don’t have to live with them.” NIDDK names aging as one cause among several, including nerve damage and infection. Replace it with a line that leaks have causes a clinician should look for.

Under 15 U.S.C. 45, deceptive acts or practices in commerce are unlawful, and 15 U.S.C. 52 prohibits false advertisements likely to induce the purchase of drugs, devices, services or cosmetics. The FTC staff Health Products Compliance Guidance says claims about the health benefits or safety of health-related products require competent and reliable scientific evidence, and that an advertiser is responsible for the claims its ads convey, including implied ones. A photo of a woman on a trampoline next to “laugh without leaking again” is a health benefit claim even without a number.

Urgent signs and 911 on every page and in every tool

A bladder clinic gets calls that are not about leaks at all: a person who cannot pass urine, sees blood, has a fever and burning, or whose sudden loss of bladder control came with weakness on one side. Put the federal signs above the booking button, in plain words: call [phone] the same day if you cannot pass urine or empty your bladder, see blood in your urine, have pain or burning when you urinate, or have a fever. Call 911 or go to an emergency room if you suddenly lose control of your bladder and have trouble talking or walking, sudden weakness, numbness or tingling in an arm or leg, loss of vision, confusion, or loss of bowel control. Ask the clinicians to review both lines before they go live.

The same wording belongs in voicemail, after-hours greetings, portal replies, text replies, chat and AI front desk tools. A tool should hand any message about sudden weakness, trouble speaking or loss of bowel control to the 911 line and alert staff, pass a person who cannot urinate or sees blood to the on-call clinician, and never offer the next open slot to a person who describes those signs. Our guides to the AI chatbot on a practice website and answering service versus AI receptionist cover how tools hand off these messages.

Phrases that need rewriting:

• “Can’t go? Book online for our next opening.” A person who cannot pass urine needs the clinic’s number and the same-day line first, and the booking form after it.
• “Text us your symptoms and we’ll get back to you.” A text line is not watched in real time. Say who reads messages and when, and give 911 for emergencies.

Laser, radiofrequency and chair offers: describe the FDA record

Search suggestions for “laser for incontinence” and “kegel chair” lead to clinics and med spas that sell device sessions for leaks, and bladder clinics receive these offers from device sellers. On July 30, 2018, FDA issued a safety communication, FDA Warns Against Use of Energy-Based Devices to Perform Vaginal “Rejuvenation” or Vaginal Cosmetic Procedures. The archived copy (content current as of March 3, 2021) says FDA had not cleared or approved any energy-based medical device for vaginal “rejuvenation” or vaginal cosmetic procedures, or for the treatment of vaginal symptoms related to menopause, urinary incontinence or sexual function, that the safety and effectiveness of these devices for those uses had not been established, and that such treatments may lead to serious adverse events, including vaginal burns, scarring, pain during sexual intercourse and recurring or chronic pain. It also says certain manufacturers may be marketing their devices outside of their cleared or approved intended uses.

That page was no longer on the FDA site when we checked on October 30, 2026, and it is more than five years old, so we searched FDA device classification and 510(k) data the same day. We found no record that lifts the 2018 statement for vaginal laser or radiofrequency treatment of leaks. The one radiofrequency device type in the classification data with stress urinary incontinence in its name is a surgical system used through the vagina or by laparoscopy, last cleared in 2002, before the warning. Separately, non-implantable electrical stimulators for incontinence are a cleared device type, with clearances as recent as September 2026, each for its own stated use. So the rule is the same for each device: describe it only in the terms of its own FDA record.

The FDA page Premarket Notification 510(k) (content current as of August 22, 2024) says FDA’s order finding a device substantially equivalent “clears” it for commercial distribution, and under 21 CFR 807.97, any representation that creates an impression of official approval of a device because of complying with the premarket notification regulations is misleading and constitutes misbranding. A chair cleared to stimulate pelvic floor muscles is not “FDA approved to cure incontinence”, and a laser cleared for a skin or surgical use is not cleared for leaks.

Phrases that need rewriting:

• “FDA-approved laser treatment for bladder leaks.” FDA said in 2018 it had not cleared or approved any energy-based device for treating vaginal symptoms related to urinary incontinence, and we found nothing newer that changes that. Remove it.
• “Vaginal rejuvenation tightens and stops leaks.” FDA called the term ill-defined and warned of burns and scarring. Remove it.
• “FDA approved chair, sit fully clothed and end leaks.” A cleared device is not approved, and “end leaks” is a result promise. Describe the device by its cleared use and say results differ.

Mesh, slings and surgery pages

Surgery pages draw readers who have seen lawsuits and news stories about mesh, and they deserve plain facts. The FDA page Urogynecologic Surgical Mesh Implants (content current as of August 16, 2021, older than two years) says that on April 16, 2019, FDA ordered the manufacturers of surgical mesh intended for transvaginal repair of pelvic organ prolapse to stop selling and distributing their products, and that mesh slings to treat stress urinary incontinence are a separate procedure with their own risks and benefits, and that it is important not to confuse the procedures. It tells people who have mesh and are satisfied, with no complications or symptoms, that no additional action is needed, and to tell their provider about persistent vaginal bleeding or discharge, pelvic or groin pain, or pain with sex.

Because that page is older than two years, check the FDA page again before a surgery page goes live, and date the check on the page. Write about slings in the NIDDK terms: a surgeon explains the risks and benefits and what kind of results a person can expect. Do not write “mesh-free means risk-free”, do not suggest that all mesh was recalled, and name no product or maker.

For devices, such as pessaries, inserts, catheters and home trainers, follow the same rule as above: describe each one by its own FDA record and cleared use, and name no product in ads. Our guide to medical device marketing claims covers intended use in full.

Supplements and “natural” bladder offers

Search suggestions for “overactive bladder natural supplements” reach clinics that sell bladder supplements at the front desk. The FDA Questions and Answers on Dietary Supplements (content current as of August 27, 2026) says FDA does not have the authority to approve dietary supplements before they are marketed. Name no product, make no claim that a supplement treats overactive bladder or stops leaks, and follow our guide to selling supplements in a medical practice. A page about natural approaches can describe what NIDDK lists: fluid timing set with a health care professional, limiting caffeine and alcohol, staying active, keeping a healthy weight, avoiding constipation, not smoking, bladder training and pelvic floor exercises.

Free pads, free assessments and prices

Free sample packs of pads, free bladder scans and free “leak assessments” are familiar offers. Two sets of rules apply. A “free” offer follows 16 CFR 251.1, which says a free offer must not be recouped through a raised price or a reduced quantity or quality elsewhere, and that the terms of the offer should be stated at the outset. And under 42 U.S.C. 1320a-7a(a)(5), civil penalties can apply to a person who offers or transfers remuneration to a Medicare or state health care program beneficiary that the person knows or should know is likely to influence the beneficiary to order or receive items or services from a particular provider, practitioner or supplier. Free supplies, gift cards or free sessions offered to people over 65 to bring them into a clinic need counsel’s review before they run.

A screening or assessment is not a diagnosis, and the page should say a provider finds the type and cause from a medical history, an exam and tests. Device sessions paid out of pocket follow our guides to advertising cash prices and good faith estimates for self-pay patients. State what a package includes, what it costs, and the refund terms if a clinician decides after the exam that the package is not the right fit. Do not sell a set number of sessions before an exam.

Coverage claims need the same care. The Medicare.gov page Physical therapy services, checked on October 30, 2026, says Part B helps pay for medically necessary outpatient physical therapy if the person is eligible, and that after the Part B deductible the person pays 20 percent of the Medicare-approved amount. Quote coverage in those terms for pelvic floor therapy, and say the clinic checks coverage for each patient’s plan rather than saying a device session “is covered by Medicare”. Our guide to marketing to Medicare patients covers the wider rules.

Referrals, device makers and supply companies

Under 42 U.S.C. 1320a-7b(b), the federal anti-kickback statute, it is a crime to knowingly and willfully offer, pay, solicit or receive any remuneration to induce or reward referrals of items or services payable by a federal health care program. Rules on referral fees are also set state by state.

For a bladder clinic, keep these points:

• Do not accept free staff, free event funding or marketing help from a device maker, a catheter or supply company or a lab tied to orders, without counsel’s review; our guide to Open Payments covers reported payments from manufacturers.
• Give patients a choice of catheter and supply companies, and do not steer orders to one company in exchange for anything of value.
• Referral programs with primary care, OB-GYN, geriatric practices, home health agencies and physical therapists follow our guide to patient and physician referrals.
• Do not pay per lead or per booked patient to a marketing company that recruits Medicare patients for device sessions or supplies.

Privacy, pixels and ads

A visit to a bladder leak page, a bladder quiz or a request for a pad sample says something about a person’s health. Keep form answers, bookings and page clicks out of tracking pixels and ad platform tools unless a written agreement covers them; our guide to tracking pixels on practice websites covers the setup. The Google Ads personalized advertising policy lists health among its sensitive interest categories and restricts targeting based on it. Ads can target by place and by search terms, and should not be built from a list of patients with incontinence.

Under 45 CFR 164.501, a reminder about the practice’s own treatment for an individual, such as a follow-up visit, can fall outside the definition of marketing, while a message that promotes a third party’s product, such as a pad brand or a supplement, generally needs a signed authorization under 45 CFR 164.508. Reminder texts, mailers and envelopes name no condition, no result and no product, since a household member may see them.

Tone and patient stories

People wait years before they mention leaks, and the copy decides whether they call. Use plain, adult words such as “bladder leaks” and “bladder control”, avoid jokes about accidents, and show the clinician’s name and license, the visit steps and who will be in the room. NIDDK tells people to talk with a health care professional even if they feel embarrassed, and a page can say the same.

A story from a patient who goes back to running is the strongest pull a bladder clinic has. Under 16 CFR 255.2, an ad that shows one person’s result on a key attribute is likely to be read as what others will generally achieve, unless the advertiser has substantiation for that or clearly and conspicuously discloses what people can generally expect. A story should not say the patient is “dry for good”, and should add a plain line that results differ and leaks can return. Get a signed authorization under 45 CFR 164.508 where the practice is a covered entity, name no device or supplement, say if the patient received anything for taking part, and let them review the final version. Our guides to patient photo consent and testimonials and before and after photos cover the full rules.

Illustration: two bladder clinic pages

Illustration: a page reads “Laugh, jump and sneeze without leaking again! Our FDA-approved laser and Kegel chair cure bladder leaks in 6 sessions, with no surgery, no pills and no downtime. 9 out of 10 women are dry for good. Book now and get a free month of pads.” It promises a cure the sources do not support, calls devices approved for a use FDA said in 2018 it had not cleared, sells a set number of sessions before an exam, uses an outcome number with no source, offers free supplies as a draw, and gives no urgent signs.

Illustration: a second page for the same practice reads “At [Practice name], [Clinician name, license] leads our bladder control clinic. Bladder leaks have causes, and treatment depends on the type and cause. Your plan may start with bladder training and pelvic floor exercises with a physical therapist, and may include medicine, a device, a bulking agent or, when other treatments have not helped, surgery. We explain each option, its risks and its cost at your visit. Call [phone] the same day if you cannot pass urine, see blood in your urine, or have burning or a fever. Call 911 if loss of bladder control comes with sudden weakness, numbness, trouble speaking or confusion. Call [phone] during [days and hours] to book.” It follows the NIDDK order of options, puts the urgent signs first, and promises nothing it cannot show.

Checklist before a bladder clinic campaign goes live

• NIDDK and MedlinePlus pages named and dated, with pages older than two years marked and checked against newer FDA label and device data at each review.
• The same-day signs and the 911 signs, plus the clinic’s number, above any booking button, in voicemail, after-hours greetings, portal replies, text replies, chat and AI front desk tools.
• No cure, “dry for good”, “one session” or “no downtime” claims; options described in the NIDDK order, with surgery named as an option.
• Laser, radiofrequency and chair offers described only in the terms of each device’s own FDA record; “cleared” never written as “approved”; no “vaginal rejuvenation” claims for leaks; no product names in ads.
• Mesh and sling pages checked against the FDA mesh page at each review; prolapse mesh and incontinence slings not confused.
• No supplement claims to treat bladder conditions; no product names.
• Free pads, assessments and sessions reviewed by counsel under 16 CFR 251.1 and 42 U.S.C. 1320a-7a(a)(5) before they run; no session packages sold before an exam; prices and refund terms stated.
• Coverage quoted from Medicare.gov and checked per patient.
• No free staff, event funding or marketing help from device makers or supply companies tied to orders without counsel’s review; patients choose their supplier.
• Form answers, quizzes and bookings stay out of pixels and ad audiences; reminders and mailers name no condition.
• Stories have signed authorizations, make no results claim, and say results differ.

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices and health businesses, including urology, OB-GYN, primary care, geriatric and pelvic floor therapy practices that run bladder clinics. For a bladder clinic, that means a site that quotes NIDDK and MedlinePlus as written and dated, puts the urgent signs and the clinic’s number above the booking button, answers “cure urinary incontinence” and “laser for incontinence” searches without a promise, and keeps device claims, free supplies and supplier ties off the page, plus referral and appointment request pages that keep answers off the web and away from tracking tools. Our front desk tools hand stroke-like signs to the 911 line and other urgent signs to the on-call number, and do not triage symptoms. We do not decide who needs treatment; your clinicians do. Our tools are built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We are not a healthcare provider and we do not give legal or medical advice. We do not sell lead lists and we do not pay for referrals. For the wider rules, see our healthcare marketing rules hub.

Sources

• NIDDK: Bladder Control Problems (Urinary Incontinence) (last reviewed July 2021)
• NIDDK: Symptoms and Causes of Bladder Control Problems (last reviewed July 2021)
• NIDDK: Treatments for Bladder Control Problems (last reviewed July 2021)
• MedlinePlus: Urinary Incontinence (last updated January 9, 2024)
• MedlinePlus encyclopedia: Urinary incontinence (review date October 1, 2024)
• openFDA: Drug labeling API (searched October 30, 2026)
• openFDA: Device 510(k) and classification APIs (searched October 30, 2026)
• FDA: safety communication on energy-based devices for vaginal rejuvenation (issued July 30, 2018; archived copy, content current as of March 3, 2021)
• FDA: Urogynecologic Surgical Mesh Implants (content current as of August 16, 2021)
• FDA: Premarket Notification 510(k) (content current as of August 22, 2024)
• 21 CFR 807.97: Misbranding by reference to premarket notification
• FDA: Questions and Answers on Dietary Supplements (content current as of August 27, 2026)
• Medicare.gov: Physical therapy services (checked October 30, 2026)
• 15 U.S.C. 45: Unfair methods of competition unlawful
• 15 U.S.C. 52: Dissemination of false advertisements
• FTC: Health Products Compliance Guidance (December 2022)
• 16 CFR 251.1: Guide concerning use of the word free and similar representations
• 42 U.S.C. 1320a-7a: Civil monetary penalties
• 42 U.S.C. 1320a-7b: Criminal penalties for acts involving Federal health care programs
• 45 CFR 164.501: Definitions
• 45 CFR 164.508: Uses and disclosures for which an authorization is required
• 16 CFR 255.2: Consumer endorsements
• Google Ads: Personalized advertising policy

More in Physician specialty marketing